FeesSafety
Pluang+

Xanamem shows 30% slowing of Alzheimer's progression in patients over 75 in Actinogen's trial

Market News
20 Nov 2026, 02:13 WIB
Proactive Investors
View Source
Bullish
Xanamem shows 30% slowing of Alzheimer's progression in patients over 75 in Actinogen's trial

Actinogen Medical reported that its drug Xanamem slowed Alzheimer's disease progression by 30% in patients over 75 during the XanaMIA trial, with 40% of these older patients experiencing no disease progression compared to 22% on placebo. Although the trial missed its primary endpoint in the overall population, the drug showed a strong safety profile and potential for use alongside existing treatments. Actinogen plans to report more data from an ongoing extension study in early 2027 and is seeking development partners to support further Phase 3 trials.

Actinogen Medical's Alzheimer's drug Xanamem is noted here alongside Pluang's Health-sector market snapshot as of Nov 20, 2026 07:01 WIB: out of 150 priced Health-sector US stocks, 20 rose and 130 fell. Among notable movers, Tilray Brands Inc (TLRY) declined 8.00% to USD 2.07 with 100% buy order activity and a typical hold time of 33 days; GeneDx Holdings Corp (WGS) dropped 6.47% to USD 48.60 with a 21-day hold; and Hims and Hers Health Inc (HIMS) fell 6.45% to USD 15.95 with 82% sell order activity and a 24-day hold.

More News

S&P 500's four-week drop after record high signals potential long-term gains, not a bear market.

S&P 500's four-week drop after record high signals potential long-term gains, not a bear market.

The S&P 500 recently experienced a four-week losing streak following a record high, dropping about 8% from its peak. Historically, such declines have often been healthy pullbacks rather than signs of a bear market, with the index showing gains six an...

Market News
Bullish
1 hour ago
Universal Technical Institute's revenue rises but profit falls, shares drop nearly 9%.

Universal Technical Institute's revenue rises but profit falls, shares drop nearly 9%.

Universal Technical Institute (UTI) reported a 6% increase in fourth-quarter revenue to $235.9 million, driven by a rise in full-time students. However, net income fell nearly 4% to just over $18 million, missing analyst earnings per share estimates....

Company Fundamentals
Bearish
1 hour ago
Michael Burry warns investors on risks in CoreWeave, Nebius, Nvidia, and chip stocks amid falling prices.

Michael Burry warns investors on risks in CoreWeave, Nebius, Nvidia, and chip stocks amid falling prices.

Investor Michael Burry highlighted risks in CoreWeave, Nebius, Nvidia, and semiconductor stocks, noting significant price drops due to rising borrowing costs and potential long-term challenges for Nvidia's competitive edge. CoreWeave and Nebius have ...

Market News
Bearish
1 hour ago
AMD's AI data center revenue nearly doubles, positioning it to challenge Nvidia's dominance.

AMD's AI data center revenue nearly doubles, positioning it to challenge Nvidia's dominance.

AMD is gaining ground on Nvidia in the AI chip market, with its data center revenue nearly doubling year over year in Q3 and overall revenue up 45%. Nvidia faces leadership uncertainty after former CEO Jensen Huang's departure, creating an opportunit...

Market News
Bullish
1 hour ago
Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's investigational drug JNJ-6143, acquired through a $3.05 billion purchase of Halda Therapeutics, demonstrated a 75% overall response rate in a Phase 1 trial for metastatic castration-resistant prostate cancer. This promising early ...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App